Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Pediatric Studies

 

Seneca Valley Virus-001 for Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features (COG-ADVL0911)
A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

Investigator: Julie Park, MD;   Conditions: Adrenocortical Carcinoma, Gastrointestinal Carcinoid Tumor, Kidney Cancer, Neuroblastoma, Retinoblastoma, Sarcoma;    Status: Closed;   Study ID: NCT01048892

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia (COG ADVL0413)
A Phase I study of the Raf kinase and receptor tyrosine kinase inhibitor Sorafenib (BAY 43-9006, NSC# 724772 IND# 69896) in children with refractory solid tumors or refractory leukemias

Investigator: Julie Park, MD;   Conditions: Refractory solid tumors , Refractory leukemias;    Status: Closed;   Study ID: NCT00343694

Cord Blood Cell Infusion Post Chemotherapy for AML (2584)
Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Induction Chemotherapy (FLAG) in Patients with Relapsed/Refractory AML

Investigator: Colleen Delaney, MD, MSc;   Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia;    Status: Recruiting;   Study ID: NCT01701323

T Cell Depleted Donor Transplant for Preventing Graft-Versus-Host Disease (2660)
A Phase II Study of Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children

Investigator: Marie Bleakley, MD;   Conditions: Leukemia;    Status: Recruiting;   Study ID: NCT01858740

Pamidronate Post Transplant for Pediatric Patients (9223)
Prevention of Bone Loss after Pediatric Hematopoietic Cell Transplantation

Investigator: K.Scott Baker;   Conditions: Hematologic Malignancies;    Status: Recruiting;   Study ID: NCT02074631

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT-01)
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01: A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Recurrent/Refractory Neuroblastoma using Autologous T-cells lentivirally transduced to express CD171-specific Chimeric Antigen Receptors

Investigator: Julie Park, MD;   Conditions: Neuroblastoma;    Status: Recruiting;   Study ID: NCT02311621

Combination of the PARP Inhibitor, Niraparib and Temozolomide for Previously Treated, Incurable Ewing Sarcoma (SC-6015)
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients with Previously Treated, Incurable Ewing Sarcoma

Investigator: Doug Hawkins, MD;   Conditions: Childhood Cancers, Miscellaneous; Sarcoma; Solid Tumors; Sarcoma, Ewing;    Status: Recruiting;   Study ID: NCT02044120